400
Participants
Start Date
September 30, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
January 31, 2009
Placebo
"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg, 10 mg and 25 mg~* Route of Administration: Oral use"
Brivaracetam 2.5 mg
"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
Brivaracetam 10 mg
"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg~* Route of Administration: Oral use"
Brivaracetam 25 mg
"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
Phoenix
Tucson
Little Rock
Fresno
Los Angeles
Newport Beach
Sacramento
San Francisco
Washington D.C.
Atlanta
Augusta
Chicago
Springfield
Wichita
Lexington
Louisville
Baltimore
Bethesda
Burlington
Detroit
Grand Rapids
Saint Paul
Tupelo
Chesterfield
St Louis
New York
Rochester
Cincinnati
Columbus
Portland
Philadelphia
Greenville
Nashville
Dallas
Houston
Salt Lake City
Charlottesville
Richmond
Seattle
Milwaukee
Chatswood
Randwick
Woodville
Clayton
Fitzroy
Parkville
Adelaide
Fitzroy
West Heidelberg
Campinas
Curitiba
Florianópolis
Porto Alegre
Ribeirão Preto
Salvador
São José do Rio Preto
São Paulo
Edmonton
Greenfield Park
Montreal
Québec
Mexico City
Monterrey
Aguascalientes
Chihuahua City
Mexico City
Monterrey
Nuevo León
San Luis Potosí City
Lead Sponsor
UCB Pharma
INDUSTRY